The trial’s primary endpoint is the mean change in HbA1c from baseline, while secondary endpoints include changes in fasting blood glucose, body weight, and overall safety
SLE remains a life-threatening autoimmune disease, with patients facing an elevated risk of early mortality and long-term organ damage
_256_384.jpg){kind=logo}
Fasting glucose improved by 12.3 mg/dL, while liver stiffness dropped 23.7%, signaling a direct hepatic benefit
Heart failure affects an estimated 64.3 million people worldwide
The Phase II study will assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of 9MW3811 in patients with pathological scarring
The trials did not show a statistically significant reduction in annualized clinical fracture rates compared to placebo or bisphosphonates
The study will run across 18 sites and enroll roughly 200 patients over 24 months
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Subscribe To Our Newsletter & Stay Updated
